Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Intellia Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -12.88%.
The industry rank for Intellia Therapeutics's 3-Year RORE % or its related term are showing as below:
NTLA's 3-Year RORE % is ranked worse than 51.74% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs NTLA: -12.88
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Intellia Therapeutics 3-Year RORE % Related Terms
Intellia Therapeutics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Intellia Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTLA vs MLYS, VCEL, NRIX: 3-Year RORE % Comparison
For the Biotechnology subindustry, Intellia Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Intellia Therapeutics (NTLA) has a 3-Year RORE % of -12.88 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Intellia Therapeutics and its competitors. According to the industry distribution chart, Intellia Therapeutics ranks #668 out of 1291 companies in the Biotechnology industry, placing it in the top 51.7%.
Is Intellia Therapeutics' 3-Year RORE % too high?
Intellia Therapeutics' current 3-Year RORE % is -12.88. Based on the distribution chart, Intellia Therapeutics ranks #668 out of 1291 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' 3-Year RORE % compare to MLYS and VCEL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #668 out of 1291 companies for 3-Year RORE %. This places Intellia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current 3-Year RORE % is -12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Significantly Undervalued. The stock's GF Value™ is $20.44, compared to a current price of $14.22 — trading 30.5% below its estimated fair value. The current 3-Year RORE % is -12.88. Intellia Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current 3-Year RORE % is -12.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $14.22 is trading 30.5% below its estimated GF Value™ of $20.44.
GuruFocus considers Intellia Therapeutics to be Significantly Undervalued.
Key valuation signals for NTLA:
3-Year RORE %: -12.88
GF Value™: $20.44 vs. price of $14.22 (30.5% below fair value)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
